What is the Targeted Translation Research Accelerator Grant Opportunity?
The 2020 Targeted Translation Research Accelerator Grant Opportunity is a scheme to deliver the Accelerator as a comprehensive package of activities to improve outcomes for diabetes and cardiovascular disease.
The 2020 Targeted Translation Research Accelerator Grant Opportunity was announced as part of the Medical Research Future Fund and is an Initiative under the Preventive and Public Health Research Initiative.
The objective of the Targeted Translation Research Accelerator Grant opportunity is to support the development of novel preventive, diagnostic and therapeutic approaches and products for diabetes and cardiovascular disease.
The successful independent organisation will be responsible for ensuring that the Accelerator:
- establishes through competitive processes two research centres, one for diabetes and one for cardiovascular disease to accelerate therapies for the prevention, early detection and treatment of disease related complications
- supports through competitive processes research projects on the potential common pathways interactions, and complexities for patients experiencing two or more of the following: Type 1 diabetes; Type 2 diabetes; and cardiovascular disease
- targets investment and related support through partnership projects to progress promising drug and device development projects, with a focus on promoting commercialisation of novel therapeutics and devices for diabetes and cardiovascular disease
- sources, nurtures and invests in early stage therapeutic research targets to transform diagnostic and therapeutic care for people with diabetes
- commissions and conducts research to support the health and commercial sectors to deliver transformations in diabetes and cardiovascular disease.
The expected outcome of the research funded through partnership projects with the independent organisation selected under the grant opportunity is to improve knowledge and its translation into practice in order to reduce the burden of diabetes and cardiovascular disease.
The Australian Government agreed a total of $125 million over nine years, in the 2018-19 Budget to progress early stage diabetes and cardiovascular disease research.
For this grant opportunity, up to $47 million is available over four years from 2019-20 to 2022-23. There is the potential for this grant to be extended up to a maximum of 10 years.
To be eligible for the Targeted Translation Research Accelerator Grant opportunity, your project must:
- be aimed at the objectives
- have no more than $47 million in eligible expenditure
- include one or more of the following eligible activities:
- employment of personnel and/or
- other direct research costs.
To be eligible for the Targeted Translation Research Accelerator Grant opportunity, you must:
- have an Australian Business Number (ABN)
- be incorporated in Australia
and in accordance with s20 and s24 of the Medical Research Future Fund Act 2015, be one of the following entities:
- a medical research institute
- a university
- a corporate Commonwealth entity
- a corporation (including businesses and not for profits)
- a state or territory government entity.
Joint applications are encouraged, provided you have a lead organisation who is the main driver of the project and is eligible to apply.
Applications close 22 April 2020.
19 January 2022 – $10m for national stroke & heart research translation accelerator
The new Research Centres are:
- The Australian Centre for Accelerating Diabetes Innovations (ACADI)
- The Australian Stroke & Heart Research Accelerator (ASHRA)
Each Centre has been awarded $10 million over four years through the Australian Government’s Medical Research Future Fund, with the University of Sydney’s Professor Clara Chow announced as ASHRA director for the first year.